Cosmetic Labeling Requirements: U.S. & EU Guide

Cosmetic labeling requirements are not one global checklist. The fields, wording, placement, language, responsible party, warnings, and claims controls depend on the destination market, product category, intended use, formula, and package. Classification and market routing should therefore happen before graphic design.

The buyer’s short answer
Freeze the product, formula revision, claims, target markets, pack dimensions, business roles, contact channel, and evidence owners. Then map each required element to the right market, panel, container layer, language, source, reviewer, and proof revision.

Attractive artwork can still fail when the ingredient declaration, net quantity, responsible-business details, claims, and target market were never controlled together. This guide is general information current to August 28, 2026; it is not legal advice, an artwork approval, or a substitute for product-specific regulatory review.

Freeze the regulatory route before the proof: one unresolved market, claim, formula revision, legal role, or panel dimension can invalidate otherwise polished artwork.

Searchers often begin with cosmetic label examples, MoCRA labeling requirements, or FDA labeling requirements for skin care products. Each is a useful starting phrase, but none supplies the product-specific classification, formula, role, package, and market facts required for a release decision.

Start with a Market and Product Classification Gate

The controlling rules follow the destination market, product definition, intended use, dosage form, claims, and any product-specific overlay. In the United States, a skincare formula may be a cosmetic, a drug, or both depending on intended use—even when the package looks like an ordinary beauty product.

The practical risk is starting design while the product category or market owner is unresolved. That failure pushes a classification decision into prepress, where a name, claim, warning, or legal role may force expensive artwork changes.

Label Jurisdiction Freeze Sheet	Question to freeze	Evidence owner	Stop condition
Market	Where will the finished product be offered?	Brand / regulatory	Country or state route is unresolved
Classification	What is the intended cosmetic function and dosage form?	Product / regulatory	Drug, sunscreen, soap, or other boundary is open
Claims	What will text, imagery, product name, and advertising imply?	Brand / evidence owner	Evidence or permitted category is unclear
Product flags	Which ingredients, warnings, application sites, users, or formats alter the route?	Formula / safety	A trigger has not been evaluated
Legal roles	Who is the named business or responsible person in each market?	Brand / market owner	Role and contact ownership conflict
Package form	Which container layers, panels, and dimensions will carry the label?	Packaging / artwork	The represented commercial pack is not frozen
Quantity	What verified fill and units will the marketed package declare?	Quality / market owner	Fill basis or unit treatment is unresolved
Language	Which market language rules apply to each required field?	Market owner / translator	Mandatory wording lacks a controlled language version
Change baseline	Which formula, pack, claim, and artwork revisions does this proof represent?	Quality / document owner	A source revision does not match the proof

FDA’s current Cosmetics & U.S. Law overview states that the agency does not preapprove cosmetic products or ingredients, apart from some color additives. “Not preapproved” does not mean unregulated, and “FDA approved” should not appear on a cosmetic merely because the business believes its label follows the rules.

A federal checklist also may not exhaust customs marking or state obligations. California, for example, maintains a separate ingredient-reporting program for products containing listed ingredients; that is a scoped state reporting overlay, not a universal federal on-pack field.

United States Cosmetic Label Requirements by Panel

The FDA Cosmetics Labeling Guide distinguishes the principal display panel from the information panel, and some statements differ between the outer and immediate containers. A phrase does not become compliant simply because it appears somewhere; its location, prominence, wording, and package context matter.

Label Element Placement Matrix	Typical location	Layer check	Source input	Approval question
Statement of identity	Principal display panel	Outer and sale presentation	Product classification	Does the name accurately identify the cosmetic?
Net quantity	Principal display panel	Sale package	Verified fill and units	Do units, location, and type size fit the actual panel?
Business name and place	Information panel	Outer / immediate rules	Legal business role	Is qualifying wording required?
Ingredient declaration	Information panel	Package-specific	Released formula reconciliation	Are name, order, and presentation verified?
Warnings / directions	Required conspicuous space	Trigger-specific	Product risk and rule	Is the exact warning triggered and readable?
Country of origin	Customs-marking route	Imported product	Origin determination	Has the import-marking owner confirmed treatment?

The FDA guide states that ingredient lettering is generally at least 1/16 inch high (about 1.6 mm) and may be at least 1/32 inch (about 0.8 mm) when the available labeling surface is less than 12 square inches. Net-quantity minimums vary with principal-display-panel area, so a single type-size value should not be copied across every pack.

English is the default language route, but an additional language can bring a requirement to repeat mandatory information in that language. Small packages, decorative containers, aerosols, and other product-specific situations need review against the actual pack rather than a generic mockup.

11-Point Rule-Language Decoder for a Label Brief

Regulatory search results often use overlapping phrases. This decoder turns that vocabulary into controlled buyer questions instead of treating repeated wording as separate requirements.

Category	Phrases encountered	Buyer interpretation
1. Required content	label information; required label information; part of the label; label statements	Name the exact statement, trigger, source, and placement.
2. Governing law	labeling regulation; cosmetic labeling regulations; Fair Packaging and Labeling Act; Federal Food, Drug, and Cosmetic Act	Cite the current provision, not the broad act name alone.
3. Industry terms	personal care; personal care product; Personal Care Products Council; cosmetics and personal care products	Industry terminology can support context but does not replace law.
4. FDA route	FDA cosmetic labeling requirements; FDA labeling; FDA regulations; FDA requirements; FDA labeling rules; FDA authority over cosmetics	Resolve the product category and exact federal provision.
5. Ingredients	ingredient labeling; cosmetic ingredient labeling; purpose of cosmetic ingredient labeling; ingredients must be listed; must be listed in descending order	Reconcile names and order to the released formula and the 1% rule.
6. Alternative delivery	off-package ingredient labeling; off-package cosmetic ingredient labeling; direct mail cosmetics; available for labeling; labeling accompanying the product	Confirm whether a specific exception permits another medium.
7. Scope	label or labeling; labeling compliance; labeling of cosmetics; labeling purposes	Separate the physical label from broader accompanying material.
8. Available surface	available to bear labeling; area available to bear labeling; panel of the label; panel of a cosmetic	Use the actual dieline and exclude surfaces the cited rule excludes.
9. Status and safety	cosmetic label must; label of a cosmetic; cosmetic misbranded; considered cosmetics; safety of a cosmetic; must bear appropriate label warnings	Test each statement against the actual product and trigger.
10. Category and nomenclature	nature of the cosmetic; cosmetic is also a drug; guide to cosmetic labeling; cosmetic ingredient dictionary	Classification precedes naming resources and layout.
11. Container and quantity	container holding the cosmetic product; immediate container holding the cosmetic; cosmetic in the container; cosmetic in the package; reveal the quantity of cosmetic; fluid measure if the cosmetic is liquid; viscous cosmetic; including decorative cosmetic containers; cosmetic manufacturers; ingredients of all products sold	Map the exact container layer, product consistency, units, and any exception.

Build an Ingredient Declaration That Matches the Formula

A defensible ingredient declaration starts with the released formula, not with a competitor label or supplier marketing sheet. Reconcile every raw material and constituent to the permitted declaration name, concentration band, order rule, color or fragrance treatment, source, and reviewer.

The root cause of many ingredient declaration failures is an unreviewed gap between a supplier composition and the commercial formula. Evidence under 21 CFR 701.3 belongs beside the reconciliation record so a reviewer can confirm why each name and order was used.

Formula-to-label reconciliation
Track formula line → raw material → reportable constituents → declaration name → concentration band → order treatment → color, fragrance, or flavor treatment → source → reviewer → variance. Hold artwork when the formula revision or a supplier composition is unresolved.

Under 21 CFR 701.3, ingredients are generally declared in descending order of predominance. Ingredients present at no more than one percent may be listed in any order after those above one percent, and color additives may follow the non-color ingredients under the rule.

International Nomenclature of Cosmetic Ingredients terminology is useful, but an ingredient list prepared for another market is not automatic proof of a correct United States declaration. Trade names can conceal multiple constituents, while supplier or formula changes can invalidate an earlier label even when the product name stays the same.

Separate Business Identity from the MoCRA Adverse-Event Contact

The business identity statement and the MoCRA adverse-event contact are related but separate data fields. 21 U.S.C. § 364e establishes the label contact requirement: a domestic address, domestic phone number, or electronic contact through which the responsible person can receive cosmetic adverse-event reports.

Business identity
Confirm the named firm, its actual role, the address basis, and whether “Manufactured for” or “Distributed by” treatment is required.

Adverse-event route
Freeze the domestic address, domestic phone, or electronic contact and the person who monitors and escalates incoming reports.

Change control
Set a notification trigger for address, role, domain, phone, inbox, vendor, or monitoring-owner changes.

FDA describes the United States responsible person as the manufacturer, packer, or distributor whose name appears on the label. The domestic contact requirement should not be confused with facility registration, product listing, safety substantiation, or the separate 15-business-day serious-adverse-event reporting clock.

Screen Warnings and Claims Before They Reach Artwork

Claims can change the regulatory route before they become polished copy. In the United States, disease prevention or treatment and structure-or-function claims may establish drug intended use; the FDA cosmetics claims guidance explains that, under the law, cosmetic claims must be truthful and not misleading.

Claim Wording Escalation Queue	Implied takeaway	Category signal	Evidence held	Decision
Exact product and claim text	What would a reasonable consumer understand?	Cosmetic, drug, or unresolved	Product-matched support	Allow / revise / remove / escalate
Disease or treatment language	Prevents, treats, heals, or mitigates disease	Drug signal	Regulatory pathway evidence	Escalate before use
Structure or function language	Changes how the body works	Drug signal	Category and substantiation review	Escalate or rewrite
Beauty-performance claim	Cleanses, beautifies, or alters appearance	Cosmetic may fit	Claim-specific evidence	Review truthfulness and scope

Trace the language across your packaging, product names, web sites, advertising, images, trademarks, distributor information, and anywhere it appears (implicitly or explicitly). A disclaimer cannot rescue an otherwise drug-defining intended use, and there is no invented universal safe harbor for “dermatologist tested,” “hypoallergenic,” “clean,” or “non-toxic.”

Warnings need their own route: universal provision, product-type warning, ingredient-triggered wording, safe-use directions, or another market-specific requirement. The correct answer comes from the exact product and rule, not from accumulating generic caution language.

European Union Article 19 Requires a Different Field Set

A United States label does not become a European Union label through translation alone. Article 19 has its own particulars, role definitions, placement routes, language allocation, durability treatment, and exceptions, all of which must be planned for the actual product and member-state market.

The compliance risk is assuming overlap means equivalence. The current consolidated Regulation (EC) No 1223/2009 provides the evidence path, because the container, packaging, language, and practical-impossibility rules belong to the exact European Union route.

Article 19 particulars checklist
Responsible-person name and address; country of origin for imported cosmetics; nominal content; minimum durability or period after opening; precautions; batch reference; product function unless clear; ingredient list; member-state language; and the permitted placement or practical-impossibility route.

The consolidated regulation requires container and packaging particulars to be indelible, easily legible, and visible. It also includes detailed alternatives for practical impossibility and small products; it does not simply erase information because the primary pack is small.

For each fragrance allergen covered by an applicable Annex III entry, Regulation (EU) 2023/1545 requires individual disclosure in the ingredient list when its concentration exceeds 0.001 percent in a leave-on product or 0.01 percent in a rinse-off product. Its placement transition ended July 31, 2026, while qualifying legacy stock may remain available until July 31, 2028; the exact substance, product, and current restriction—including later amendments reflected in the May 18, 2026 consolidated text—determine whether that transition applies.

Claims require a separate evidence review. Regulation (EU) No 655/2013 applies to explicit and implicit claims across media and organizes the review around legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making.

Use a United States–European Union Gap Matrix

One master data set can reduce transcription errors, but shared data does not make the final artwork interchangeable. Compare the legal role, wording, symbol, language, placement, and evidence for every field before deciding whether any artwork element can be reused.

The risk appears when a shared ingredient or quantity field is copied because it looks familiar. United States Part 701 rules and European Union requirements use different role, placement, and language logic, so the gap matrix records both the common source and the market-specific expression.

Field	United States route	European Union route	Shared data?	Open check
Business / responsible party	Manufacturer, packer, distributor; MoCRA responsible person	European Union responsible person	Sometimes	Role, address, qualifying wording
Quantity	Net quantity and presentation rules	Nominal content with exceptions	Source fill may be shared	Units, symbols, placement
Ingredients	21 CFR 701.3 declaration	Article 19 ingredient list	Formula source may be shared	Names, order, allergens, exceptions
Durability	No universal cosmetic expiration field	Minimum durability or period after opening route	Study data may inform both	Market expression and symbol
Claims	Truthful, not misleading, category-safe	Article 20 plus six common criteria	Underlying evidence may overlap	Exact market claim and context
Language and layers	English default; outer/immediate mapping	Member-state language; container/packaging routes	No automatic reuse	Each panel, leaflet, tag, or card

Assign Artwork Inputs, Checks, Approval, and Retention

Printing or filling a package does not automatically make that party the final legal approver. The brand, responsible person, formulator, manufacturer, packaging supplier, designer, translator, regulatory reviewer, quality approver, and printer need an explicit handoff for each controlled input.

Artwork Source-and-Signoff Register	Source owner	Verification evidence	Reviewer / approver	Retained record
Formula revision and ingredient declaration	Formulator / manufacturer	Released reconciliation	Quality / regulatory	Formula and label revision
Claims and substantiation	Brand / evidence owner	Claim file matched to wording	Regulatory / legal as applicable	Approved claim and source
Panels, dimensions, and print limits	Packaging supplier / printer	Current dieline and specification	Packaging / prepress	Dieline and proof revision
Roles, address, and contact	Brand / responsible entity	Entity and monitoring confirmation	Market owner	Approved role record
Translation and market particulars	Qualified translator / regulatory	Source-to-target review	Member-state / market reviewer	Language approval and final proof

Required inputs include the formula revision, exact claims, pack dimensions, net or nominal quantity, market, legal identities, contact route, warnings, directions, languages, symbols, and proof revision. A manufacturing partner may supply or check data within an agreed scope, but a web page or service contract cannot be used to infer every legal role or final approval.

Reopen Review When a Label-Bearing Fact Changes

An earlier approval represents the facts recorded at that time. Reopen impact assessment when a formula, claim, supplier composition, package surface, quantity, business role, contact, language, market, warning, regulation, or artwork fact changes—even when the edit looks minor.

The recurring risk is silent reuse: because a prior proof still looks familiar, a team can miss a failure in the formula-to-label link. Recheck the official FDA labeling source or current European Union regulation whenever the trigger ledger shows a market-bearing change.

Artwork Revision Impact Record
Record change → affected field → previous evidence → impact assessment → market → reviewer → action → proof revision → approval date. Use four decision states: no label impact with rationale; controlled data update; market-specific review; or new substantiation / reclassification escalation.

A raw-material substitution can change constituent naming; a new claim can change classification; a smaller panel can change presentation; a new country can change language and role details; and a contact-domain change can break the adverse-event route. “Text-only” and “same formula name” are not impact assessments.

Brief a White-Label Skincare Manufacturing Partner

A stock skincare formula does not make the label automatically ready. Before requesting artwork, prepare one controlled brief containing the formula and revision, product identity, exact claims, target markets, responsible entities, quantity, packaging drawings, ingredient-declaration source, warnings, directions, contact channel, languages, evidence, owners, and unresolved questions, with the applicable regulator source beside each controlled field.

NEXO Beauty Labs is a global cosmetic original-equipment and original-design manufacturing partner specializing in skincare, hair care, and body care development, formulation, and scalable manufacturing. Its manufacturing foundation dates to 1999, and its international team has supported global partners since 2020; these company facts do not by themselves establish a legal-review service, certification, guarantee, capacity, minimum order, lead time, or client result.

Brands preparing a formula, claims, pack, and market brief can review NEXO skincare development support before starting an artwork handoff.

Bring the unresolved facts into one brief
Prepare your formula, target market, packaging drawing, exact claims, and open label questions, then open a development discussion with NEXO Beauty Labs.

Frequently Asked Questions

What are the requirements for cosmetic labeling?

Cosmetic labeling requirements depend on the destination market, product classification, claims, formula, and package. In the United States, a typical review covers the statement of identity, net quantity, business name and place, ingredient declaration, required warnings, and conspicuous placement on the appropriate panel. MoCRA also added adverse-event contact information. Product-specific exceptions and drug-type claims can change the route, so use the current regulation and regulator guidance for the actual product rather than a generic template.

Do I need FDA approval to sell cosmetics?

The United States Food and Drug Administration generally does not preapprove cosmetic products or cosmetic labels before sale, except that color additives require approval for their intended use. That does not remove the company’s responsibility: the product must be safe for consumers under labeled or customary conditions, and the label must not be false or misleading. Claims can also make a product a drug, which introduces a different regulatory pathway. Confirm the category and every claim before treating “no preapproval” as permission to launch.

Can the same cosmetic label be used in the United States and European Union?

Sometimes a shared data set can support both labels, but the final artwork should not be assumed interchangeable. The two markets differ in legal roles, required particulars, language, durability or period-after-opening treatment, adverse-event contact, claims framework, country-of-origin treatment, and presentation details. Build a field-by-field gap matrix for the actual formula and pack. Reuse only the information that truly matches, then obtain market-specific review for wording, symbols, placement, and responsible entities.

Is INCI naming mandatory on United States cosmetic labels?

International cosmetic ingredient nomenclature is widely used, but the legally required United States declaration must follow 21 CFR 701.3 and the names permitted or required there. Reconcile the exact formula and constituents against the applicable United States naming and order rules.

Who is responsible for private-label cosmetic compliance?

Responsibility depends on the destination market and the roles actually held by the brand, United States responsible person, European Union responsible person, manufacturer, packer, or distributor. A contract manufacturer may provide formula, production, packaging, and change-notice inputs within its agreed scope, but that participation does not automatically transfer every statutory duty or final-artwork decision. The named business may need qualifying wording; the responsible person may need a monitored adverse-event contact; and the market owner may need to retain claim support, safety information, translations, approval records, and current proofs. Contracts should assign who supplies each data field, who checks it against source evidence, who approves the market version, who receives regulatory or supplier changes, who handles adverse events, and who retains the final record. If two parties believe the other owns a task, mark it unresolved and stop the proof rather than printing on assumption.

One practical next step
Run the routing gate, placement matrix, claim screen, responsibility handoff, and change ledger before releasing a proof. When the inputs are controlled, contact NEXO Beauty Labs to discuss the manufacturing brief.

Primary References

The References & Sources below support the regulatory distinctions and buyer checks used throughout this guide.

The five named decision tools in this article are editorial syntheses of public sources. They are not NEXO standard operating procedures, legal opinions, regulatory approvals, or proof of a NEXO compliance service.